|
1 Introduction to Basic Immunology and Techniques |
|
|
1 | (18) |
|
|
|
1 | (3) |
|
1.1 Basic immunology and techniques |
|
|
4 | (2) |
|
|
6 | (2) |
|
|
8 | (1) |
|
1.4 Antigen-antibody reactions |
|
|
9 | (1) |
|
1.5 Antibody mediated red cell destruction |
|
|
10 | (3) |
|
1.6 In vitro detection of antigen-antibody reactions |
|
|
13 | (4) |
|
|
17 | (2) |
|
|
18 | (1) |
|
2 Human Erythrocyte Antigens or Blood Groups |
|
|
19 | (26) |
|
|
|
19 | (2) |
|
2.1 The ABO, H, and Lewis blood group systems |
|
|
21 | (5) |
|
2.2 The Lewis blood group system and secretor |
|
|
26 | (1) |
|
2.3 The MNS blood group system |
|
|
27 | (2) |
|
2.4 The Rh, RHAG, and LW blood group systems |
|
|
29 | (6) |
|
2.5 The Lutheran blood group system |
|
|
35 | (2) |
|
2.6 The Kell and Kx blood group systems |
|
|
37 | (2) |
|
2.7 The Duffy blood group system |
|
|
39 | (2) |
|
2.8 The Kidd blood group system |
|
|
41 | (1) |
|
2.9 The P1PK blood group system |
|
|
42 | (1) |
|
|
42 | (3) |
|
|
43 | (1) |
|
|
44 | (1) |
|
3 Donors and Donation: Collection and Processing |
|
|
45 | (24) |
|
|
|
45 | (1) |
|
|
46 | (5) |
|
3.2 Donor/donation linking |
|
|
51 | (1) |
|
3.3 Component preparation |
|
|
52 | (9) |
|
|
61 | (4) |
|
3.5 Component validation and labelling |
|
|
65 | (4) |
|
|
67 | (1) |
|
|
68 | (1) |
|
|
69 | (29) |
|
|
|
69 | (1) |
|
|
70 | (11) |
|
4.2 Additional (discretionary) testing |
|
|
81 | (3) |
|
4.3 Microbiology serology testing |
|
|
84 | (4) |
|
4.4 Microbiology positive screen and confirmatory testing |
|
|
88 | (2) |
|
4.5 Bacterial contamination |
|
|
90 | (2) |
|
4.6 West Nile virus (WNV) |
|
|
92 | (1) |
|
4.7 Other threats to the blood supply |
|
|
93 | (1) |
|
4.8 Quality control/British working standards |
|
|
94 | (4) |
|
|
96 | (1) |
|
|
97 | (1) |
|
5 Clinical Use of Blood Components |
|
|
98 | (19) |
|
|
|
|
98 | (1) |
|
5.1 Structure and function of blood |
|
|
99 | (1) |
|
5.2 Normal physiological response to anaemia and/or bleeding |
|
|
99 | (1) |
|
5.3 Blood components available and their appropriate use |
|
|
100 | (5) |
|
|
105 | (1) |
|
|
106 | (1) |
|
5.6 Decision making, who needs a transfusion, risks and benefits |
|
|
107 | (2) |
|
5.7 Alternatives to donor blood |
|
|
109 | (5) |
|
5.8 Case history examples |
|
|
114 | (3) |
|
|
115 | (1) |
|
|
115 | (2) |
|
6 Compatibility Testing and Adverse Effects |
|
|
117 | (25) |
|
|
|
|
117 | (1) |
|
6.1 Compatibility testing (serological and non-serological) |
|
|
118 | (8) |
|
6.2 Selection of plasma products |
|
|
126 | (1) |
|
6.3 Selection of cellular components |
|
|
127 | (1) |
|
6.4 Visual inspection and labelling of the units |
|
|
128 | (1) |
|
6.5 Traceability of blood components |
|
|
129 | (1) |
|
6.6 Adverse effects of transfusion |
|
|
129 | (3) |
|
6.7 Monitoring the patient during transfusion |
|
|
132 | (2) |
|
6.8 Investigation of transfusion reactions |
|
|
134 | (2) |
|
6.9 Haemovigilance in the UK |
|
|
136 | (6) |
|
|
140 | (1) |
|
|
141 | (1) |
|
7 Immune Red Cell Destruction |
|
|
142 | (20) |
|
|
|
142 | (1) |
|
7.1 What is immune (antibody mediated) red cell destruction? |
|
|
143 | (2) |
|
7.2 Clinical significance of red cell antibodies |
|
|
145 | (2) |
|
7.3 Haemolytic transfusion reactions |
|
|
147 | (2) |
|
7.4 Autoimmune haemolytic anaemias |
|
|
149 | (5) |
|
7.5 Haemolysis post-transplantation bone marrow/stem cell transplant |
|
|
154 | (1) |
|
7.6 Haemolytic disease of the newborn or foetus (HDN) |
|
|
155 | (7) |
|
|
160 | (1) |
|
|
160 | (2) |
|
8 Human Leucocyte Antigens and Their Clinical Significance |
|
|
162 | (25) |
|
|
|
162 | (1) |
|
8.1 A brief history of transplantation |
|
|
163 | (1) |
|
8.2 Human leucocyte antigens |
|
|
163 | (7) |
|
8.3 The detection and definition of human leucocyte antigens, alleles, and antibodies |
|
|
170 | (4) |
|
8.4 Clinical significance of human leucocyte antigens in transplantation |
|
|
174 | (7) |
|
8.5 Clinical significance of human leucocyte antigens in transfusion |
|
|
181 | (6) |
|
|
185 | (1) |
|
|
186 | (1) |
|
|
186 | (1) |
|
9 Human Platelet Antigens (HPA) and Human Neutrophil Antigens (HNA) and Their Clinical Significance |
|
|
187 | (30) |
|
|
|
188 | (1) |
|
9.1 Overview of platelet and granulocyte antigens |
|
|
188 | (2) |
|
9.2 Human platelet antigens (HPA) |
|
|
190 | (6) |
|
9.3 Human neutrophil antigens (HNA) |
|
|
196 | (3) |
|
|
199 | (6) |
|
9.5 Clinical significance of HPA alloantibodies |
|
|
205 | (7) |
|
9.6 Clinical significance of HNA antibodies |
|
|
212 | (5) |
|
|
215 | (1) |
|
|
215 | (1) |
|
|
216 | (1) |
|
10 Haemopoietic Stem Cell Banking |
|
|
217 | (19) |
|
|
|
217 | (1) |
|
|
218 | (2) |
|
10.2 Major histocompatibility complex and human lymphocyte antigens |
|
|
220 | (2) |
|
10.3 Sources of haemopoietic stem cells |
|
|
222 | (2) |
|
10.4 Stem cell collection and processing |
|
|
224 | (6) |
|
10.5 Reinfusion and engraftment |
|
|
230 | (1) |
|
|
231 | (2) |
|
10.7 Health and safety, and statutory requirements |
|
|
233 | (1) |
|
10.8 The future of stem cell therapy |
|
|
234 | (2) |
|
|
235 | (1) |
|
|
235 | (1) |
|
|
236 | (22) |
|
|
|
236 | (1) |
|
|
237 | (1) |
|
11.2 Which tissues are banked and how are they used? |
|
|
238 | (2) |
|
11.3 How are donors selected, screened, and consented? |
|
|
240 | (3) |
|
11.4 How are tissues retrieved? |
|
|
243 | (4) |
|
11.5 Tissue processing and preservation |
|
|
247 | (7) |
|
11.6 Storage and distribution |
|
|
254 | (1) |
|
11.7 The future-regenerative medicine |
|
|
255 | (3) |
|
|
256 | (1) |
|
|
257 | (1) |
|
|
258 | (14) |
|
|
|
|
258 | (1) |
|
12.1 Evolution of quality |
|
|
258 | (3) |
|
12.2 Quality management systems |
|
|
261 | (3) |
|
12.3 Blood safety and quality regulations |
|
|
264 | (3) |
|
12.4 The In Vitro Diagnostic Medical Devices Directive |
|
|
267 | (1) |
|
12.5 Clinical laboratory accreditation |
|
|
267 | (1) |
|
12.6 The Blood Stocks Management Scheme |
|
|
268 | (1) |
|
12.7 Other legislation and regulatory bodies |
|
|
269 | (1) |
|
|
270 | (1) |
|
|
270 | (2) |
|
|
271 | (1) |
|
|
271 | (1) |
Glossary |
|
272 | (4) |
Abbreviations |
|
276 | (3) |
Index |
|
279 | |